SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes.

Mingyang Sun et al.PubMed ↗Full text ↗Publisher ↗

SGLT2ilooks good hereFewer deaths, lower PD.Randomised, small.

What the trial testedrandomised · 2025

Randomised vs metformin

Probably reduced deaths

−15%−17% to −11%

SGLT2i vs metformin

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.85, 95% CI 0.83–0.89 · the paper's word: all-cause mortality

Not counted

Probably lowered PD

−28%−38% to −16%

SGLT2i vs metformin

Bigger than 6 in 10 on the map

As reported

HR 0.72, 95% CI 0.62–0.84

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

SGLT2i

metformin

Probably reduced deaths−15%

Probably lowered PD−28%

randomised

the abstract, start to end

… 28% lower PD risk than metformin (aHR = 0.72; 95% CI, 0.62-0.84; …

… lower all-cause mortality (aHR = 0.85; 95% CI, 0.83-0.89; …

← favours treatmentfavours comparator →

could be chance

PDSGLT2i vs metformin

HR 0.720.62–0.84

All-cause mortalitySGLT2i vs metformin

HR 0.850.83–0.89

SGLT2 inhibitorsAll-cause mortalityPharmacokinetics & dosing

1 / 5

1 paper cites it

2025

2026

this papercites it

SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes.

What the trial testedrandomised · 2025

Probably reduced deaths

Probably lowered PD

Who was studied, and how

Two numbers in the abstract

Where each one falls

Only readable comparisons vote

Where it lands on the map

1 paper cites it